Early Access — free while we kick the tires
EdgarHawk

Shulman Joseph

Chief Technical Officer

Officer
3 filings analyzed · 1 company · Latest 2025-11-03

Companies

Company Buys Sells Direction
RHYTHM PHARMACEUTICALS, INC. RYTM 0 10 Net selling

Activity

November 2025
high
Sell
9,748 shares
$1,123,398
Significance 6/10

CTO Joseph Shulman sold 9,748 shares of RYTM at $115.24 (Oct 30), reducing stake by 53.4% to 8,509 shares; stock up 14.9% in 30 days.

Joseph Shulman, Chief Technical Officer, executed a substantial sale reducing his RYTM holdings by 53.4%, divesting 9,748 shares at $115.24 on a stock trading near its 52-week high of $113.89 and up 14.9% over the prior 30 days. His cross-ticker track record shows 10 prior sells with a 90d well-timed rate of 100.00%, though this represents sales that preceded stock declines; however, same-ticker history at RYTM is mixed—only 1 of measurable sales outcomes was well-timed at the 90-day mark, and the most recent prior sale (2025-10-16) outcome is not yet measurable. The company is scaling revenue (+68.1% annual growth) but remains unprofitable ($-46.6M net income on $48.5M quarterly revenue), creating a fundamental risk profile that may warrant scrutiny of insider positioning during periods of strong momentum.

October 2025
high
Sell
14,437 shares
$1,617,337
Significance 7/10

CTO Joseph Shulman sells 14,437 shares (62.9% reduction) for $1,617,336.81 at $112.03 blended average

Joseph Shulman, Chief Technical Officer, executed 3 separate sales on 2025-10-16 totaling 14,437 shares for $1,617,336.81, reducing his holdings from 22,946 to 8,509 shares—a 62.9% reduction in position size at a blended average price of $112.03. The current stock price of $112.39 is at the 52-week high, and the company has demonstrated strong recent momentum (+17.0% over 30 days, +28.0% over 90 days) despite being unprofitable with a quarterly net loss of $46,632,000.00. Notably, Shulman's prior 4 measurable sells at RYTM were all well-timed at the 90-day mark (stock fell after each sale), and his broader cross-ticker track record shows a 100.00% well-timed rate on 7 prior sells with an average 90-day return of -22.7%, establishing a consistent pattern of selling into strength before subsequent declines. This substantial liquidation at the stock's 52-week high, combined with his demonstrated ability to time exits, warrants attention in the context of the company's unprofitable status and elevated valuation.

September 2025
high
Sell
16,781 shares
$1,767,006
Significance 8/10

CTO Shulman Joseph sold 16,781 shares (66.4% of holdings) at $105.30 for $1.8M; prior 5 RYTM sales all declined 90-days post-trade.

Joseph Shulman, Chief Technical Officer, executed a substantial open-market sale of 16,781 shares at $105.30 on 2025-09-02, reducing his position from 25,290 to 8,509 shares and realizing $1.8M in proceeds. The timing signal is notable: his five prior sales at RHYTHM over early 2024 all resulted in negative 90-day returns, with a consistent pattern of declines ranging from -13.1% to -23.8%. His cross-ticker track record shows a 100.00% well-timed sell rate across 6 prior sales (average 90d return -22.7%), suggesting a demonstrated ability to sell ahead of downside. The stock currently trades at $104.57, only 0.0% below its 52-week high, having surged +18.1% in 30 days and +53.5% in 90 days—a peak from which an insider with a consistent track record of identifying sell windows may perceive elevated risk. The company remains unprofitable on an annual basis despite +68.1% revenue growth, and Joseph has now divested two-thirds of his remaining stake at what appears to be a tactical inflection point.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access